Spanish biotech Ona Therapeutics secures $86.6 million Series B to advance new ADCs for breast and colorectal cancer
Ona Therapeutics, a Barcelona‑based biotechnology startup, announced a Series B financing round that raised roughly $86.6 million.
The new capital will fund the launch of two antibody‑drug conjugates (ADCs) into clinical development, with programs aimed at advanced breast cancer and colorectal cancer.
ADCs are an established pillar of cancer therapy, with more than 20 products already approved. Ona plans to differentiate its candidates by targeting novel mechanisms that could overcome drug resistance.
The sizable investment reflects investor confidence in the company’s next‑generation ADC platform and positions it to compete with larger firms developing similar oncology treatments.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “A Spanish biotech banks $87M to make differentiated ADCs”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that